Conference Coverage
Conference Coverage
Is prescribing stimulants OK for comorbid opioid use disorder, ADHD?
One new study showed that from 2007-2017, there was a threefold increase in OUD and comorbid ADHD.
Conference Coverage
Cancer risk tied to some manufactured foods
The results of three European studies support the removal of trans fatty acids, nitrites, and nitrates from food products.
Conference Coverage
Breast cancer-related musculoskeletal pain alleviated with acupuncture
A new study shows that electroacupuncture and auricular acupuncture may relieve debilitating chronic musculoskeletal pain for breast cancer...
Conference Coverage
How does atopic dermatitis present in skin of color?
Morphological variants common in skin of color include the follicular variant or micropapular variant of AD.
Conference Coverage
HIV testing dips during pandemic raise transmission concerns
The number of CDC-funded HIV tests declined by more than 1 million in 2020 amid the COVID-19 restrictions.
Conference Coverage
Abrocitinib efficacy dose-dependent, similar across AD age groups
“We know that responses to, and adverse events associated with, systemic therapies may vary among patients of different ages.”
Conference Coverage
Home-based system relieves refractory ascites in cirrhosis
A tunneled peritoneal catheter drainage system relieved symptoms with an infection risk similar to standard of care.
Conference Coverage
CRP elevated in adults with AD and sleep disturbance
“There is a consequence of not treating patients with atopic dermatitis, especially those patients with sleep disturbance.”
Conference Coverage
Inadequate routine diabetes screening common in HIV
People with HIV are known to be at an increased risk of diabetes and the long-term complications of the disease.
Conference Coverage
Sacituzumab govitecan effective in Black mTNBC patients
Black women may have outcomes comparable to those of other women when given sacituzumab govitecan for the treatment of metastatic TNBC, suggests...
Conference Coverage
PD-L1 cutoff for pembrolizumab in mTNBC confirmed
PD-L1 CPS of at least 10 improves overall survival by 28%-29%. Further analysis of responses to pembrolizumab plus chemotherapy in metastatic TNBC...